Here are the latest stories being discussed in biopharma today:

CG Oncology’s IPO: A Sign of Healthier Public Offerings in Biotech?

CG Oncology’s $380 million IPO has kicked off the year, offering a glimmer of hope for a stronger year of biotech public offerings. Whilst industry insiders are cautious about predicting trends from individual companies, CG Oncology’s success indicates encouraging signs for the future. At least another five biotech companies are set to follow shortly.

Details Emerge on Secondary Cancer Cases Following CAR-T Treatment

FDA officials have shared information showing more than half of investigated cancer cases occurring within two years of CAR-T therapy. They are currently investigating 22 incidents where T cell cancers developed after CAR-T cell treatment.

Kyverna Optimizes CAR-T Production Times

Kyverna Therapeutics has shed more light on how blood collection efficiencies can shorten manufacture times for autoimmune CAR-T therapy. Their process, called Ingenui-T, reduces the lengthy and complicated process of leukapheresis, traditionally used to separate T cells from blood donations.

Shanghai Startup’s Breakthrough in Restoring Hearing for Deaf Children

Shanghai Refreshgene Therapeutics has reported an exciting breakthrough as their gene therapy restored hearing for five out of six deaf children in a recent study. This puts the company ahead of larger drug developers, such as Eli Lilly and Regeneron, in the race to develop effective gene therapies for hearing loss.

Cabometyx-Tecentriq Combination Shows Promise in Combatting Prostate Cancer

A combination of Roche’s Tecentriq and Exelixis’ Cabometyx has offered hope for stalling advanced prostate cancer. Patients saw disease progression halted for a longer period than with a secondary hormone therapy, showing that this combination therapy could be an effective option in the future.

Headspace Predicts Cash-Flow Positivity by 2024

Mental health startup Headspace has projected it will be cash-flow positive by the first quarter of 2024, a year earlier than originally planned. Instead of a public launch, Headspace has shifted its focus to profitability, relying more on sales to employers than consumers.